Edwards Lifesciences Corp
Financial highlights
| Metric | FY 12/31/25 | FY 12/31/24 | FY 12/31/23 | FY 12/31/22 | FY 12/31/21 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $6.1 | $5.4 | $5.0 | $4.5 | $5.2 |
| Operating income | $1.3 | $1.4 | $1.3 | $1.5 | $1.7 |
| Net income | $1.1 | $4.2 | $1.4 | $1.5 | $1.5 |
| Cash Flow Statement | |||||
| Free cash flow | $1.3 | $0.3 | $0.6 | $1.0 | $1.4 |
| Share repurchases | $0.9 | $1.2 | $0.9 | $1.7 | $0.5 |
Shares outstanding 576.4M · Free float 99.7%
Annual filing data through FY ended December 31, 2025; float as of October 10, 2026.